OBJECTIVES: A safe and effective topical prevention strategy will likely require sustained delivery of potent antiviral drugs and a delivery system that simultaneously maximizes drug distribution and overcomes the behavioural challenges related to adherence. Activity against HIV and herpes simplex virus (HSV) would be advantageous, given the epidemiological link between the two pathogens. We hypothesize that tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, may be more potent than tenofovir and ideal for sustained intravaginal ring (IVR) delivery. METHODS: The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models. Cumulative tenofovir DF release and stability from polyether urethane (PEU), ethylene-co-vinyl acetate (EVA) and silicone IVRs were compared, and the activity and safety of drug released were evaluated in cervical explants and in a polarized dual-chamber model. RESULTS: Tenofovir DF inhibited HIV and HSV at ≈ 100-fold lower concentrations than tenofovir and retained activity in the presence of semen. PEU rings delivered >1 mg/day of tenofovir DF for 30 days. Pre-treatment of cervical explants with 10 μg/mL tenofovir DF or eluants from PEU minirings resulted in >90% inhibition of HIV and reduced HSV-2 yields by 2.5 log. Tenofovir DF and eluants did not prevent cell growth or polarization, or have any deleterious effects on an epithelial barrier. CONCLUSIONS: The findings support the development of a PEU tenofovir DF ring, which may provide potent and sustained protection against HIV and HSV.
OBJECTIVES: A safe and effective topical prevention strategy will likely require sustained delivery of potent antiviral drugs and a delivery system that simultaneously maximizes drug distribution and overcomes the behavioural challenges related to adherence. Activity against HIV and herpes simplex virus (HSV) would be advantageous, given the epidemiological link between the two pathogens. We hypothesize that tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, may be more potent than tenofovir and ideal for sustained intravaginal ring (IVR) delivery. METHODS: The anti-HIV and anti-HSV activity of tenofovir and tenofovir DF were assessed in cell and explant models. Cumulative tenofovir DF release and stability from polyether urethane (PEU), ethylene-co-vinyl acetate (EVA) and silicone IVRs were compared, and the activity and safety of drug released were evaluated in cervical explants and in a polarized dual-chamber model. RESULTS:Tenofovir DF inhibited HIV and HSV at ≈ 100-fold lower concentrations than tenofovir and retained activity in the presence of semen. PEU rings delivered >1 mg/day of tenofovir DF for 30 days. Pre-treatment of cervical explants with 10 μg/mL tenofovir DF or eluants from PEU minirings resulted in >90% inhibition of HIV and reduced HSV-2 yields by 2.5 log. Tenofovir DF and eluants did not prevent cell growth or polarization, or have any deleterious effects on an epithelial barrier. CONCLUSIONS: The findings support the development of a PEUtenofovir DF ring, which may provide potent and sustained protection against HIV and HSV.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: B C Herold; A Siston; J Bremer; R Kirkpatrick; G Wilbanks; P Fugedi; C Peto; M Cooper Journal: Antimicrob Agents Chemother Date: 1997-12 Impact factor: 5.191
Authors: Patricia S Fletcher; Julie Elliott; Jean-Charles Grivel; Leonid Margolis; Peter Anton; Ian McGowan; Robin J Shattock Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: Marla J Keller; Lianna Wood; James M Billingsley; Laurie L Ray; Jessica Goymer; Shada Sinclair; Aileen P McGinn; Mark A Marzinke; Bruce Frank; Sujatha Srinivasan; Congzhou Liu; Jessica M Atrio; Lilia Espinoza; Nelly Mugo; Hans M L Spiegel; Peter L Anderson; David N Fredricks; Craig W Hendrix; Jeanne Marrazzo; Steven E Bosinger; Betsy C Herold Journal: Lancet HIV Date: 2019-07-15 Impact factor: 12.767
Authors: R Karl Malcolm; Claire J Forbes; Leslie Geer; Ronald S Veazey; Laurie Goldman; Per Johan Klasse; John P Moore Journal: J Antimicrob Chemother Date: 2012-10-30 Impact factor: 5.790
Authors: Briana Nixon; Thomas Jandl; Ryan S Teller; Ekaterina Taneva; Yanhua Wang; Umadevi Nagaraja; Patrick F Kiser; Betsy C Herold Journal: Antimicrob Agents Chemother Date: 2013-12-09 Impact factor: 5.191
Authors: Marc M Baum; Irina Butkyavichene; Scott A Churchman; Gilbert Lopez; Christine S Miller; Thomas J Smith; John A Moss Journal: Int J Pharm Date: 2015-09-16 Impact factor: 5.875
Authors: Jennifer Mait-Kaufman; Esra Fakioglu; Pedro M M Mesquita; Julie Elliott; Yungtai Lo; Rebecca Pellett Madan Journal: AIDS Res Hum Retroviruses Date: 2015-04-08 Impact factor: 2.205
Authors: James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: Nicholas J Giannasca; Jennifer S Suon; Amanda C Evans; Barry J Margulies Journal: J Drug Deliv Sci Technol Date: 2019-11-13 Impact factor: 3.981